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Malaria remains a major killer of young children and an
enormous economic drain on developing countries. The
purpose of this conference panel was to explore two major
initiatives to build capacity for prevention and control of
malaria.
Roll Back Malaria
Awash Teklehaimanot, acting project manager for Roll
Back Malaria (RBM), described its initiative. Each year, more
than 300 million clinical cases of acute malarial illness occur,
mainly affecting the world’s poorest populations. More than 1
million people die each year from malaria, and 90% of these
deaths occur in children in sub-Saharan Africa. Malaria is
also a substantial impediment to human development in poor
countries. It slows economic growth in Africa by up to 1.3%
each year; the short-term benefits of malaria control have
been estimated at U.S. $3 to $12 billion per year. Malaria is a
growing concern as antimicrobial resistance against multiple
drugs becomes more widespread and malaria develops in
areas previously malaria-free.
The RBM partnership, launched by World Health
Organization (WHO) Director-General Grö Harlem Brundt-
land in October 1998, is committed to cutting the global
malaria burden in half by 2010. In Africa, where most malaria
occurs, the RBM partnership builds on a history of malaria
control and a political commitment to eliminating the disease,
which has never been higher. For example, the African Heads
of State Summit to Roll Back Malaria, held in Abuja, Nigeria,
on April 25, 2000, marked the first meeting of African political
leaders to discuss the human and economic consequences of
malaria on their continent. At the summit, heads of several
development agencies pledged $750 million in new money and
discussed concrete action to be taken over the next decade.
The core elements of RBM strategy include 1) ensuring
rapid diagnosis and early treatment within or near the home;
2) making insecticide-treated mosquito nets (ITNs) available
and increasing access to other vector control measures, such as
environmental management to control mosquitoes; 3) making
pregnancy safer through preventive intermittent malaria
treatment for pregnant women; 4) improving epidemic
preparedness through improved surveillance and appropriate
rapid response; and 5) supporting focused research to develop
new medicines, vaccines, and insecticides.
To implement these core interventions on a large-scale,
the RBM partnership recognizes the need to 1) strengthen the
capacity of health systems and services; 2) work with and
through other sectors such as education, public works,
women’s development, agriculture, and local government; 3)
involve other groups, such as those in the private sector, and
4) sponsor focused applied research and development of
effective tools and approaches. In addition, technical support
networks comprised of experts with practical experience and
from various institutions have been established to provide a
link between universities, disease control operations, and
international experts.
Some recent promising developments include ITNs with
long-lasting insecticide; initiatives to create commercially
sustainable markets for ITNs; more effective and less
expensive antimalarial drug combinations; concerted efforts
to reduce tariffs and taxes on antimalarial commodities, such
as drugs and nets; and partnerships with other international
health programs, such as the Integrated Management of
Childhood Illness program, to both ensure more efficient
health systems that address all diseases of poverty and to
improve medical treatment of children. For further
information about RBM, please visit their website at
www.rbm.who.int.
Multilateral Initiative on Malaria
Gerald Keusch described the Multilateral Initiative on
Malaria (MIM) as an alliance of organizations and
individuals working together to increase malaria research in
Africa and to facilitate global collaboration, coordination, and
capacity-building. MIM’s roots can be traced back to 1995
when the National Institutes of Health (NIH) organized an
initial planning meeting. This was followed in 1997 by an
international conference in Dakar, Senegal, which was
notable for the prominent role played by African malaria
research scientists. After follow-up meetings in The Hague
and in London, MIM was officially launched in late 1997, with
the first secretariat housed at the Wellcome Trust. In 1999
the 1st International MIM Conference was held in Durban,
South Africa, to bring the malaria research and control
communities together. MIM’s secretariat is intended to rotate
among member organizations; since June 1999, it has been
housed at the Fogarty International Center of NIH.
MIM has several objectives: 1) to raise international
public awareness of the problem of malaria; 2) to promote
global communication and cooperation on malaria; 3) to
develop sustainable malaria research capacity in Africa; and
4) to ensure that research findings are applied to malaria
treatment and control.
To date, MIM has had several notable accomplishments.
With funding from NIH, the World Bank, the Rockefeller
Foundation, WHO, and the governments of Norway, France,
and Japan, MIM and WHO’s Tropical Disease Research
(TDR) program formed a MIM-TDR Research and Capacity-
Building Grants Program. To date, 20 grants have been given
through which $6 million has been distributed. The grants
embody several of the guiding principles of MIM, such as an
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emphasis on partnerships, decision-making by African
scientists, and a strong scientific basis for the funded
research. To support a variety of research programs, MIM has
also developed the Malaria Research and Reference Reagent
Resource Center, which provides high quality reagents and
materials to investigators who are, or wish to be, involved in
malaria research. NIH’s National Library of Medicine has
taken responsibility for enhancing the capacity of African
scientists to do research by establishing and supporting
access to communications and information resources. A
number of research networks are online using very small
aperture telecommunications (VSAT) technology for Internet
access. This allows for shared databases, electronic mail and
discussion groups, access to published literature, and use of
remote sensing technologies. Information about the progress
of MIM is shared through meetings, a newsletter, and on the
internet at http://mim.nih.gov
Future goals of MIM include stabilizing funding for the
MIM-TDR grant program, developing new partnerships, and
creating new training opportunities, such as training on
research management. Scientific research on Plasmodium
vivax  and on malaria-related anemia is being conducted.
Interactions with RBM are well-established and coordinated.
The 2nd International MIM Conference is scheduled for 2002
in Tanzania.
Institutional review boards (IRBs) play an essential
role in protecting the rights of volunteers involved in
research projects. Their function has become more complex,
particularly concerning projects conducted in developing
countries. But can IRBs in the United States guarantee the
protection of human subjects involved in research projects
in developing countries?
IRBs have no effective way of controlling what goes on in
the field. The complex ethical clearance process does not
determine whether persons engaged in research projects in
developing countries are fully aware of the major aspects of
the studies they participate in. The clearance process includes
the IRB approval and consent forms. Required U.S. consent
forms are too long and the language too complicated to be
certain all participants have a full understanding of the
study. The forms also appear to be intended more to offer legal
protection to sponsoring agencies than to protect the welfare
of the volunteer. Most importantly, the forms do not
guarantee that volunteers have fully understood the
objectives, risks, and benefits of the study and the extent of
their voluntary participation. To protect volunteers as well as
all persons and institutions involved, these forms must not
only communicate necessary information concerning the
study to be conducted but also evaluate volunteers’ knowledge
and their desire to participate. To achieve this goal, we propose
to use a simple questionnaire administered by a team not
involved in the volunteer recruitment process. We have used
such a questionnaire to evaluate potential volunteers for a
phase-II HIV vaccine trial. Although volunteers had three
intensive, 2-hour counseling sessions, only half responded
correctly to all 21 questions. The others were referred for
additional counseling and reevaluation.
The IRB process requires that collaborative projects with
U.S. institutions have clearance from multiple IRBs. Each
IRB meets generally once a month and uses its own consent
forms. Each has its own set of rules. Each will respond with
different concerns that must be addressed. The approval
process may create a lag time of 3 to 12 months to obtain
ethical clearances for a project lasting 12 to 24 months.
The ethical clearance process can be simplified in several
ways: 1) All studies supported by NIH should have a unique
IRB application form and a unique IRB consent form. 2) A
certain percentage of the research grant should be allocated to
support the ethical clearance process. Ethical support should
be available at the grant’s initiation. 3) While waiting for the
formal ethical clearance and final consent, potential
volunteers could be counseled and evaluated. 4) The primary
responsibility of local and national IRBs should be clearly
determined. IRBs must share responsibilities to achieve the
greatest benefit for volunteers. 5) A mechanism must be
developed to resolve conflicts between IRBs from developed
and developing countries. Yearly meetings of IRBs from host
and sponsoring institutions should take place to facilitate the
exchange of documents and other information.
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